🇪🇺EU · EMAWithdrawnATC: L04AB04

Cyltezo(adalimumab)

Hidradenitis Suppurativa;Arthritis, Psoriatic;Psoriasis;Crohn Disease;Arthritis, Juvenile Rheumatoid;Uveitis;Arthritis, Rheumatoid;Colitis, Ulcerative;Spondylitis, Ankylosing

Marketing Authorisation Holder: Boehringer Ingelheim International GmbH

EMA Authorisation: 10/11/2017

INN: adalimumab

Indication

Please refer to section 4.1 of the Summary of product characteristics in the product information document.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cyltezo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Cyltezo Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.